12:44 PM EDT, 07/18/2025 (MT Newswires) -- Sarepta Therapeutics' ( SRPT ) gene therapy Elevidys is under US Food and Drug Administration review, as the agency is evaluating whether it should remain on the market, Bloomberg News reported Friday, citing FDA Commissioner Marty Makary.

The FDA was already looking into two earlier patient deaths linked to Elevidys, the media outlet reported.

Sarepta reportedly disclosed on Thursday that a third patient died during a trial involving another gene therapy that uses a similar viral delivery system.

Shares of the company were down 26% in recent trading.

Sarepta did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 16.31, Change: -5.67, Percent Change: -25.79